The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability
暂无分享,去创建一个
Michael B. Elowitz | Francis Barany | Marc Ladanyi | Richard Gorlick | M. Elowitz | A. Levine | M. Ladanyi | F. Barany | P. Rao | M. Overholtzer | R. Favis | R. Gorlick | Reyna Favis | Pulivarthi H. Rao | Arnold J. Levine | Michael Overholtzer | Xin-Yan Lu | X. Lu
[1] C. Ostwald,et al. p53 mutational spectra are different between squamous‐cell carcinomas of the lip and the oral cavity , 2000, International journal of cancer.
[2] S. Mai,et al. Genomic instability and apoptosis are frequent in p53 deficient young mice , 1997, Oncogene.
[3] Charles J. Sherr,et al. The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.
[4] M M Weiss,et al. Comparative genomic hybridisation. , 1999, Molecular pathology : MP.
[5] D. Smith,et al. p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.
[6] J. Varley,et al. Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts , 2000, British Journal of Cancer.
[7] J. Shah,et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. , 2001, Cancer research.
[8] A. Levine,et al. Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.
[9] S. Powell,et al. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control , 2000, Oncogene.
[10] A. Levine,et al. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Levine,et al. The p53 tumour suppressor gene , 1991, Nature.
[12] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[13] D. Malkin,et al. p53 and the Li-Fraumeni syndrome. , 1993, Cancer genetics and cytogenetics.
[14] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[15] A. Levine,et al. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.
[16] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[17] C. Purdie,et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. , 1994, Oncogene.
[18] P. Ambros,et al. Chromosomal regions involved in the pathogenesis of osteosarcomas , 2000 .
[19] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[20] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[21] M. Oren,et al. Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.
[22] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[23] R. Katakura,et al. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.
[24] S. Knuutila,et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.
[25] M. Ridanpää,et al. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[26] D. Notterman,et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.
[27] S. Lenk,et al. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments. , 2000, Cancer detection and prevention.
[28] H. von der Maase,et al. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. , 2002, Journal of the National Cancer Institute.
[29] J. Eyfjörd,et al. p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.
[30] L. Wiesmüller,et al. DNA Substrate Dependence of p53-Mediated Regulation of Double-Strand Break Repair , 2002, Molecular and Cellular Biology.
[31] S. Knuutila,et al. DNA sequence copy number increase at 8q: A potential new prognostic marker in high‐grade osteosarcoma , 1999, International journal of cancer.
[32] I. Bièche,et al. Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer , 1998, International journal of cancer.
[33] Shengyun Fang,et al. Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.
[34] L. Wiesmüller,et al. Dissociation of the recombination control and the sequence-specific transactivation function of P53 , 1999, Oncogene.
[35] W. Foulkes,et al. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. , 1995, British Journal of Cancer.
[36] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[37] H. Liber,et al. Homologous and Nonhomologous Recombination Resulting in Deletion: Effects of p53 Status, Microhomology, and Repetitive DNA Length and Orientation , 2000, Molecular and Cellular Biology.
[38] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[39] T. Yagi,et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. , 1993, Oncogene.
[40] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[41] V. Challa,et al. Cerebrovascular Pathology in Alzheimer's Disease and Leukoaraiosis , 2000, Annals of the New York Academy of Sciences.
[42] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[43] F. Barany,et al. Mutation Detection in K‐ras, BRCA1, BRCA2, and p53 Using PCR/LDR and a Universal DNA Microarray , 2000, Annals of the New York Academy of Sciences.
[44] D. Pinkel,et al. Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.
[45] A. Levine,et al. Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein , 1998, The EMBO journal.
[46] Patrick J. Paddison,et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.
[47] R. Weichselbaum,et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. , 1992, Cancer research.
[48] Genes, chromosomes & cancer , 1995 .
[49] Robert A. Weinberg,et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 , 1994, Nature Genetics.
[50] G. Wahl,et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.
[51] J. Niland,et al. The MDM2 gene amplification database. , 1998, Nucleic acids research.
[52] A. Levine,et al. The p53 functional circuit. , 2001, Journal of cell science.
[53] J. Dahm-Daphi,et al. Loss of wild-type p53 function is responsible for upregulated homologous recombination in immortal rodent fibroblasts. , 2000, International journal of radiation biology.
[54] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[55] A. Wyllie,et al. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability , 1999, Oncogene.
[56] Emma Jones,et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma , 2000 .
[57] B. Kennedy,et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.
[58] R. Romagnoli,et al. Malignant tumors of the osteogenic matrix. , 1998, European journal of radiology.
[59] B. Vogelstein,et al. Mutational spectra and immunohistochemical analyses of p53 in human cancers. , 1992, Chest.